Kintara Therapeutics KTRA Stock
Kintara Therapeutics Price Chart
Kintara Therapeutics KTRA Financial and Trading Overview
| Kintara Therapeutics stock price | 0.13 USD |
| Previous Close | 3.77 USD |
| Open | 3.83 USD |
| Bid | 0 USD x 3000 |
| Ask | 0 USD x 900 |
| Day's Range | 3.61 - 3.83 USD |
| 52 Week Range | 2.7 - 20 USD |
| Volume | 9.56K USD |
| Avg. Volume | 36.34K USD |
| Market Cap | 6.35M USD |
| Beta (5Y Monthly) | 0.92183 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.22 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 150 USD |
KTRA Valuation Measures
| Enterprise Value | 11.8M USD |
| Trailing P/E | N/A |
| Forward P/E | -7.3529415 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.7 |
Trading Information
Kintara Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.92183 |
| 52-Week Change | -62.50% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 20 USD |
| 52 Week Low | 2.7 USD |
| 50-Day Moving Average | 3.2 USD |
| 200-Day Moving Average | 5.37 USD |
KTRA Share Statistics
| Avg. Volume (3 month) | 36.34K USD |
| Avg. Daily Volume (10-Days) | 23.18K USD |
| Shares Outstanding | 1.69M |
| Float | 1.66M |
| Short Ratio | 0.38 |
| % Held by Insiders | 0.63% |
| % Held by Institutions | 4.18% |
| Shares Short | 25.41K |
| Short % of Float | 1.50% |
| Short % of Shares Outstanding | 1.50% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:50 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -108.15% |
| Return on Equity (ttm) | -254.47% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -16845000 USD |
| Net Income Avi to Common (ttm) | -17130000 USD |
| Diluted EPS (ttm) | -12.06 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 5.2M USD |
| Total Cash Per Share (mrq) | 3.07 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 2.156 |
| Book Value Per Share (mrq) | -4.054 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -15349000 USD |
| Levered Free Cash Flow (ttm) | -9545625 USD |
Profile of Kintara Therapeutics
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 9920 Pacific Heights Blvd |
| ZIP | 92121 |
| Phone | 858 350 4364 |
| Website | https://www.kintara.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 3 |
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Q&A For Kintara Therapeutics Stock
What is a current KTRA stock price?
Kintara Therapeutics KTRA stock price today per share is 0.13 USD.
How to purchase Kintara Therapeutics stock?
You can buy KTRA shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Kintara Therapeutics?
The stock symbol or ticker of Kintara Therapeutics is KTRA.
Which industry does the Kintara Therapeutics company belong to?
The Kintara Therapeutics industry is Biotechnology.
How many shares does Kintara Therapeutics have in circulation?
The max supply of Kintara Therapeutics shares is 39.04M.
What is Kintara Therapeutics Price to Earnings Ratio (PE Ratio)?
Kintara Therapeutics PE Ratio is now.
What was Kintara Therapeutics earnings per share over the trailing 12 months (TTM)?
Kintara Therapeutics EPS is -5.22 USD over the trailing 12 months.
Which sector does the Kintara Therapeutics company belong to?
The Kintara Therapeutics sector is Healthcare.
Kintara Therapeutics KTRA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}